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Abstract
Background: The number of individuals with a visual impairment in the UK was estimated a few years ago to be
around 1.8 million. People can be visually impaired from birth, childhood, early adulthood or later in life. Those with visual
impairment are subject to health inequities and increased risk for patient safety incidents in comparison to the general
population. They are also known to be at an increased risk of experiencing medication errors compared to those without
visual impairment. In view of this, this review aims to understand the issues of medication safety for VI people.
Methods/design: Four electronic bibliographic databases will be searched: MEDLINE, Embase, PsycInfo and CINAHL. Our
search strategy will include search combinations of two key blocks of terms. Studies will not be excluded based on
design. Included studies will be empirical studies. They will include studies that relate to both medication safety and
visual impairment. Two reviewers (SG and LR) will screen all the titles and abstracts. SG, LR, RM, SCS and PL will perform
study selection and data extraction using standard forms. Disagreements will be resolved through discussion or third
party adjudication. Data to be collected will include study characteristics (year, objective, research method, setting,
country), participant characteristics (number, age, gender, diagnoses), medication safety incident type and characteristics.
Discussion: The review will summarise the literature relating to medication safety and visual impairment.
Keywords: Medication safety, Visual impairment
Background
Visual impairment (VI) refers to a condition where the
person has a reduction in their visual acuity or field of vi-
sion, which cannot be corrected by spectacles or contact
lenses. It is estimated to affect 285 million people, 39 mil-
lion of whom are blind [1]. The number of individuals
with a visual impairment in the UK was estimated a few
years ago to be around 1.93 million [2]: about 3% of the
adult population [3]. People can be visually impaired from
birth, childhood, early adulthood or later in life. People
over 50 represent the largest group of blind and visually
impaired people, which currently stands at 82% of the
blind and visually impaired population worldwide [1].
Those with visual impairment or blindness are reported to
be marginalised in terms of accessing healthcare informa-
tion and facilities, and they are known to receive sub-
optimal healthcare [4]. Marginalised patients, such as
those with visual impairment, are subject to health inequi-
ties and increased risk for patient safety incidents in com-
parison to the general population [5]. Studies also suggest
that people with VI are more at risk of social isolation [6],
which could further perpetuate their increased risk of be-
ing affected by patient safety incidents. Those with visual
impairment are known to be at an increased risk of
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experiencing medication errors [7] compared to those
without visual impairment. This could be for a number of
reasons, such as being unable to open medication con-
tainers, being unable to differentiate various types of
medication containers, being unable to differentiate vari-
ous types of tablets/capsule dosage forms, forgetting to
take medication on time and taking the wrong medication
[7, 8]. Medicine-taking is complex and requires various
and coordinated forms of work on the part of the patient
and those in their networks. People with VI may not be
able to perform their medicine work as easily as those
without VI. The importance of supporting visually im-
paired patients to help improve their medication safety
was further strengthened in 2016 when NHS England in-
troduced the Accessible Information Standard (AIS),
which required that the information and communication
needs of disabled patients are proactively addressed in all
aspects of NHS healthcare, including the dispensing of
medicines [9]. Digital solutions are increasingly used to
improve people’s safety and quality of life and VI people
are frequent users of the Internet to support their well-
being [10, 11]. There are concerns about the cost and lack
of universal availability of this technology [12], and it is
less clear how digital technologies, managed by individ-
uals, can not only empower visually impaired people, but
also safeguard them from harm related to medication
management [13].
Rationale
To understand the issues of medication safety for VI
people, it is essential to gather evidence from their experi-
ence and consider that alongside previous research. We
have undertaken focus groups with VI people identifying a
number of key themes, including the variation in VI and
consequences for medication safety. We propose conduct-
ing a scoping review of existing research evidence to in-
crease the understanding of VI and medication safety.
The issues of medication safety for people with VI de-
pend on the nature/severity of the visual condition. Pre-
vious research conducted by the team [14] identified
that health and social care practitioners lack knowledge
and understanding of VI, but many people with VI feel
confident to explain what works for them and find “work
arounds” to maintain safety in medicine taking.
With an ageing population in many developing coun-
tries, the number of people with age-related vision loss
is likely to increase. The scoping review aims to identify
the specific medication safety issues for people with vis-
ual impairment and how these patients manage their
medicines to mitigate against medication safety issues.
Objective of the scoping review
To identify and analyse the existing literature relating to
the association between medication safety and visual
impairment, including the main types of and contribu-
tory factors to medication safety issues.
Methods
Firstly, “to examine the extent, range and nature of re-
search activity; this type of rapid review might not de-
scribe research findings in any detail but is a useful way
of mapping fields of study where it is difficult to visualise
the range of material that might be available.” The sec-
ond common reason is determining whether a system-
atic review is feasible and of value. The third and fourth
common reasons seem to describe scoping reviews that
are not exploratory or preparatory, but done in their
own right. Other authors similarly state that scoping re-
views are used to synthesise research evidence and are
often used to map existing literature in a given field in
terms of its nature, features and volume. As such, scop-
ing reviews have also been called “mapping” reviews. Fi-
nally, a map of the range of the available evidence can
be undertaken as a preliminary exercise prior to the con-
duct of a systematic review. If we wish to conduct other
more systematic reviews, then this review will allow us
to see where and if that might be possible.
Search strategy
Four electronic bibliographic databases will be searched:
MEDLINE, Embase, PsycInfo and CINAHL. We will also
identify eligible studies by checking the reference lists of
those studies identified in the search that meet our in-
clusion criteria. Our search strategy will include search
combinations of two key blocks of terms: visual impair-
ment and medication safety (Table 1), similar to those
used in two previous reviews [15, 16].
The proposed search terms are shown in Table 1.
Eligibility criteria
Studies will be excluded if they fail to meet any of the 3
criteria (a “NO” choice). Studies will be eligible for full-
text screening if they fully (a “YES” choice to each criter-
ion) or partly (one or more “UNSURE” choice) meet cri-
teria A1, A2 and A3.
A. For any study type (including review articles and
opinion pieces):
1) Is it an empirical research?
YES, NO, UNSURE
2) Does it make reference to medication safety or
medicines management?
YES, NO, UNSURE
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Types of studies: We will include empirical studies
which provide data on medication safety or medicines
management for visually impaired patients. Study
designs will not be restricted and will include both quan-
titative designs (that is, randomised controlled trials,
quasi-experimental studies, cohort studies, cross-
sectional studies) and qualitative studies including case
studies. We will also include grey literature reports.
Types of participants: patients with visual impairment.
We will not exclude participants on the basis of
comorbidities
Fig. 1 PRISMA flowchart
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Phenomena of interest: medication safety/medicines
management issues for visually impaired patients. On
the basis of previous research, we anticipate that such is-
sues may include being unable to open medication con-
tainers, being unable to differentiate various types of
medication containers, being unable to differentiate vari-
ous types of tablets/capsule dosage forms, forgetting to
take medication on time and taking the wrong medica-
tion and polypharmacy (Zhi-Han, 2017: Cheraghi-Sohi
et al, 2014.
Setting/context: Studies conducted in any setting. We
will not restrict our search in specific geographical areas
or date of publication.
We will exclude:
 Non-empirical studies
 Case studies reporting a new onset of visual
impairment following medication use
 Articles in non-English languages
Management of search outcomes and study eligibility
screening
The results of the searches of each database will be
exported to COVIDENCE [1] and duplicates deleted.
Using PRISMA guidelines (Moher et al, 2009), screen-
ing will be completed in two stages (see Fig. 1). Initially,
the titles and abstracts of the identified studies will be
screened for eligibility (see the “Eligibility criteria” sec-
tion). A proportion of titles and abstracts (50%) will be
screened by two researchers independently to assess reli-
ability using the kappa statistic. Assuming reliability is
confirmed, screening of the remaining titles and ab-
stracts will be completed by one reviewer.
Next, the full texts of studies initially assessed as “rele-
vant” for the review will be retrieved and checked
against our inclusion/exclusion criteria. Full-text screen-
ing will be completed by two members of the research
team independently, with disagreements resolved by
discussion.
Methodological quality of the studies
As scoping reviews aim to provide a map of what evi-
dence has been produced as opposed to seeking only the
best available evidence to answer a particular question
related to policy and practice, a formal assessment of
methodological quality of the included studies of a scop-
ing review will not be performed.
Data synthesis
A narrative synthesis will be conducted and the results
will be organised according to the research aims. The
first section of the results will present the research find-
ings on the association between medication safety and
visual impairment, the main types of patient safety issues
encountered by people with visual impairment and the
key contributory factors. The second section will focus
on presenting the available evidence on the use of digital
technologies for managing medication among people
with visual impairment. In the third section, we will out-
line future research recommendations for designing and
testing digital interventions to improve medication safety
in people with visual impairment. We will take into con-
sideration the present findings as well as the broader lit-
erature (from existing systematic reviews) on the use of
digital technologies in improving medication safety.
Discussion
This review will summarise the literature relating to vis-
ual impairment and medication safety. Four electronic
bibliographic databases will be searched, using combina-
tions of two key blocks of search terms: visual impair-
ment and medication safety. The findings from this
review will provide an evidence base for further work in
this area. It will increase understanding of the issues that
visually impaired people face in relation to medication
safety and ultimately improve quality of health care.
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